Development Pipeline

Poziotinib

• EGFR or HER2 Exon 20 Insertion Mutation-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
  Phase 1 Phase 2 Phase 3 Approved
• HER2-Positive Metastatic Breast Cancer
  Phase 1 Phase 2 Phase 3 Approved
• HER2-Positive Advanced or Metastatic Breast Cancer in Combination With T-DM1
  Phase 1 Phase 2 Phase 3 Approved

ROLONTIS^® (eflapegrastim)

• Chemotherapy-Induced Neutropenia (ADVANCE)
  Phase 1 Phase 2 Phase 3 Approved
• Chemotherapy-Induced Neutropenia (RECOVER)
  Phase 1 Phase 2 Phase 3 Approved

Apaziquone

• Non-Muscle Invasive Bladder Cancer (CONQUER)
  Phase 1 Phase 2 Phase 3 Approved